New presentations of Viread launched and licence extended for use in younger patients

The nucleotide analogue tenofovir (Viread) has been licensed for use in young children with HIV infection and adolescents with hepatitis B.

Tenofovir diphosphate (the active metabolite of tenofovir disoproxil fumarate) inhibits HIV-1 reverse transcriptase and the HBV polymerase. | SCIENCE PHOTO LIBRARY
Tenofovir diphosphate (the active metabolite of tenofovir disoproxil fumarate) inhibits HIV-1 reverse transcriptase and the HBV polymerase. | SCIENCE PHOTO LIBRARY

Viread can now be prescribed, in combination with other antiretrovirals, for children aged 2 years and older with HIV-1 infection. In addition, it may be used to treat chronic hepatitis B in adolescents aged 12 years and older with compensated liver disease, evidence of active viral replication, persistently elevated ALT levels and histological evidence of active inflammation and/or fibrosis.

New tablets and granules now available

In order to support dosing in children aged 6–12 years, Gilead has launched three new strengths of Viread tablets: 123mg (for children 17–22kg); 163mg (for children 22–28kg); and 204mg (for children 28–55kg). An oral granule formulation is also now available for children aged 2–6 years and for patients of all ages when a solid dosage form is not appropriate. The granules should be mixed with soft food (eg, yoghurt) before being taken.

Discontinue if renal dysfunction develops in children

Tenofovir is not recommended for use in children with renal impairment and should be discontinued in children who develop renal impairment.

View Viread drug records

Further information: Gilead Sciences

Follow MIMS on Twitter


Read these next

Stribild: a combined four-drug once-daily treatment for HIV

Stribild: a combined four-drug once-daily treatment for HIV

Stribild is a combination tablet containing elvitegravir,...


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.